Phase 3 Recruiting Industry
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in Missouri: - Site 18 — St Louis, Missouri
Phase 3 Recruiting Industry
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in Missouri: - Washington University School Of Medicine — St Louis, Missouri
Phase 3 Recruiting Network
This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05451004
Sites in Missouri: - MU Health - University Hospital/Ellis Fischel Cancer Center — Columbia, Missouri
Phase 2 Recruiting NIH
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Missouri: - Saint Francis Medical Center — Cape Girardeau, Missouri
- Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
- Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Mercy Hospital South — St Louis, Missouri
Phase 2 Recruiting NIH
This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it fi…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06029270
Sites in Missouri: - Mercy Hospital South — St Louis, Missouri
- Mercy Hospital Saint Louis — St Louis, Missouri
Phase 2 Recruiting NIH
This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cispl…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07195734
Sites in Missouri: - University of Kansas Cancer Center - Briarcliff — Kansas City, Missouri
- University of Kansas Cancer Center - North — Kansas City, Missouri
- University of Kansas Cancer Center - Lee's Summit — Lee's Summit, Missouri
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Missouri: - Local Institution - 2147 — Bolivar, Missouri
- Washington University Infusion Center Pharmacy — St Louis, Missouri
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Missouri: - Washington University — St Louis, Missouri
Phase 1, Phase 2 Recruiting Industry
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Sponsor: AstraZeneca
NCT ID: NCT07115043
Sites in Missouri: - Research Site — St Louis, Missouri
Phase 2 Recruiting Academic/Other
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer. Oropharynx SCC (OPSCC) is a common sub-type of HNSCC. Each year, 16,000 new cases of OPSCC are diagnosed in the USA. Most cases of OPSCC (\>90%) are caused by t…
Sponsor: Washington University School of Medicine
NCT ID: NCT06702033
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 2 Recruiting Academic/Other
This randomized phase II trial will characterize the efficacy, adverse event (AE) profile, and safety of two regimens of 5-FU given as 2L+ treatment to patients with RM-HNSCC. Eligible patients for this trial will have previously received …
Sponsor: Washington University School of Medicine
NCT ID: NCT07419464
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 2 Recruiting Academic/Other
This is a phase 2 trial to assess the safety and tolerability of three schedules of CUE-101 administered in the neoadjuvant phase before standard of care (SOC) therapy to treatment naïve, HLA-A\*0201 positive patients with newly diagnosed,…
Sponsor: Washington University School of Medicine
NCT ID: NCT04852328
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Missouri: - Washington University in St Louis — St Louis, Missouri
Phase 1 Recruiting Industry
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
Sponsor: Alterome Therapeutics, Inc.
NCT ID: NCT06533059
Sites in Missouri: - Research Site — St Louis, Missouri
Phase 1 Recruiting Industry
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumo…
Sponsor: Exelixis
NCT ID: NCT06545331
Sites in Missouri: - Exelixis Clinical Site #5 — St Louis, Missouri
Phase 1 Recruiting Industry
This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.
Sponsor: Solve Therapeutics
NCT ID: NCT06771219
Sites in Missouri: - Washington University — St Louis, Missouri
Phase 1 Recruiting Academic/Other
This is a phase I trial of CA-4948 in combination with FOLFOX/PD-1 inhibitor with or without trastuzumab for unresectable gastric, GEJ, and esophageal cancer. During the Dose Escalation portion of the study, different dose levels of CA-494…
Sponsor: Washington University School of Medicine
NCT ID: NCT05187182
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Missouri: - Mercy Oncology and Hematology - Clayton-Clarkson — Ballwin, Missouri
- Central Care Cancer Center - Bolivar — Bolivar, Missouri
- Cox Cancer Center Branson — Branson, Missouri
- Mercy Cancer Center - Cape Girardeau — Cape Girardeau, Missouri
- Saint Francis Medical Center — Cape Girardeau, Missouri
NA Recruiting Academic/Other
This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Missouri: - Mercy Oncology and Hematology - Clayton-Clarkson — Ballwin, Missouri
- Central Care Cancer Center - Bolivar — Bolivar, Missouri
- Cox Cancer Center Branson — Branson, Missouri
- Mercy Cancer Center - Cape Girardeau — Cape Girardeau, Missouri
- Saint Francis Medical Center — Cape Girardeau, Missouri
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Missouri: - Massive Bio SYNERGY-AI site — Kansas City, Missouri
- Massive Bio SYNERGY-AI site — St Louis, Missouri
NA Recruiting NIH
The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for mult…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06995898
Sites in Missouri: - Saint Luke's Hospital of Kansas City — Kansas City, Missouri
- Washington University School of Medicine — St Louis, Missouri
Recruiting Industry
The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.
Sponsor: Tempus AI
NCT ID: NCT06163534
Sites in Missouri: - Oncology Hematology Associates — Springfield, Missouri
- Washington University in St. Louis — St Louis, Missouri
Recruiting Academic/Other
The overall objectives of this BETRNet Research Center (RC) are: 1. to conduct a rigorous, integrated spectrum of transdisciplinary human research in Barrett's esophagus (BE) and esophageal adenocarcinoma (ECA) 2. to increase the biologica…
Sponsor: Case Western Reserve University
NCT ID: NCT00288119
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Recruiting Industry
This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-u…
Sponsor: Elephas
NCT ID: NCT07327489
Sites in Missouri: - Mercy Hospital - SPG — Springfield, Missouri
- Mercy Hospital - South — St Louis, Missouri
- Mercy Hospital -STL — St Louis, Missouri
Recruiting Industry
A total of at least 1,000 participants with suspicion of cancer including at least 107 subjects who will be diagnosed with OSCC or OPSCC will be enrolled from either primary or secondary care centers in the U.S. Clinicians will use Viome c…
Sponsor: Viome
NCT ID: NCT06174428
Sites in Missouri: - Missouri School of Dentistry & Oral Health — St Louis, Missouri